denileukin difitox

also known as DAB389IL-2 · ONTAK

Developed for: primary cutaneous T-cell lymphoma
Investigated by: Eisai Inc. · Ligand Pharmaceuticals · National Cancer Institute (NCI) · Tufts Medical Center

today NCT00211198 · Ph 4

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT00211198	May 2001 → Jan 2005	primary cutaneous T-cell lymphoma	Eisai Inc.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	denileukin difitox	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00211198 ↗
Known as	DAB389IL-2	“ONTAK (denileukin difitox, DAB389IL-2)” NCT00211198 ↗
Known as	ONTAK	“ONTAK (denileukin difitox, DAB389IL-2)” NCT00211198 ↗